1. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
- Author
-
Johnson, Isla M., Karrar, Omer, Rana, Masooma, Iftikhar, Moazah, Chen, Sunny, McCullough, Kristen, Saliba, Antoine N., Al‐Kali, Aref, Alkhateeb, Hassan, Begna, Kebede, Litzow, Mark, Hogan, William J., Shah, Mithun, Patnaik, Mrinal M., Pardanani, Animesh, Hermann, Joerg, Tefferi, Ayalew, and Gangat, Naseema
- Subjects
ACUTE myeloid leukemia ,NON-ST elevated myocardial infarction ,VENETOCLAX ,PERICARDITIS ,MYOCARDIAL infarction ,CARDIOVASCULAR diseases risk factors - Abstract
Summary: Among 301 newly diagnosed patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent, 23 (7.6%) experienced major cardiac complications: 15 cardiomyopathy, 5 non‐ST elevation myocardial infarction and/or 7 pericarditis/effusions. Four patients had more than one cardiac complication. Baseline characteristics included median age ± interquartile range; 73 ± 5 years; 87% males; 96% with cardiovascular risk factors; and 90% with preserved baseline ejection fraction. In multivariate analysis, males were more likely (p = 0.02) and DNMT3A‐mutated cases less likely (p < 0.01) to be affected. Treatment‐emergent cardiac events were associated with a trend towards lower composite remission rates (43% vs. 62%; p = 0.09) and shorter survival (median 7.7 vs. 13.2 months; p < 0.01). These observations were retrospectively retrieved and warrant further prospective examination. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF